Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma ...

In September, commenced patient dosing to investigate evorpacept plus SARCLISA® (isatuximab-irfc) and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM) in the ...

Sanofi will keep a significant stake in the ... Another great milestone is the approval with Sarclisa in the US for adult patients with newly diagnosed multiple myeloma ineligible for transplantation.

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

were reported The results of Sanofi’s phase 3 IMROZ trial have allowed for the expanded indication of Sarclisa. Previously approved only for patients with previously treated multiple myeloma (MM), the ...

It also vowed to keep Opella's headquarters in France, the same source added. Read also: USFDA nod to Sanofi Sarclisa in combo with bortezomib, lenalidomide, dexamethasone for newly diagnosed multiple ...

French pharmaceutical group Sanofi experienced a profitability boom in the third ... Tzield - for type 1 diabetes -, Sarclisa (multiple myeloma) and Rezurock, used in cases of graft-versus-host ...